Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2017 /
Lymphoma highlights from ASCO annual meeting 2017

14th - 16th Jul 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.07.17
Views: 1674

Dr Eduardo Sotomayor - George Washington Cancer Center, Washington, USA

Dr Sotomayor talks with ecancer at the Best of ASCO 2017 meeting in Miami about the highlights from the ASCO annual meeting in the field of lymphoma. He discusses two abstracts with long term follow up of patients treated for follicular lymphoma, the first is the phase 3 study evaluating the efficacy and safety of bendamustine plus rituximab verses a standard rituximab-chemotherapy regimen, the BRIGHT study. The second is a phase 3 study looking at bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment, the StiL study.

For more information on recent developments in lymphoma treatment watch ecancers coverage of the EHA conference here

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation